Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
Evanthia T Roussos TorresChristine I RafieChenguang WangDavid LimAdam BrufskyPatricia LoRussoJoseph Paul EderVincent ChungMelinda DownsMolly GeareRichard L PiekarzHoward StreicherLeslie AnforthMichelle A RudekQingfeng ZhuSepideh BesharatiAshley Cimino-MathewsRobert A AndersVered StearnsElizabeth D ThompsonRoisin M ConnollyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The combination of entinostat with nivolumab ± ipilimumab was safe and tolerable with expected rates of immune-related AEs. Preliminary evidence of both clinical efficacy and immune modulation supports further investigation.
Keyphrases